Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease
出版年份 2014 全文链接
标题
Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease
作者
关键词
-
出版物
Expert Opinion on Drug Metabolism & Toxicology
Volume 10, Issue 6, Pages 839-857
出版商
Informa Healthcare
发表日期
2014-03-26
DOI
10.1517/17425255.2014.902444
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Safety and Efficacy of Metformin in Patients With Type 2 Diabetes Mellitus and Chronic Hepatitis C
- (2014) Kira Harris et al. ANNALS OF PHARMACOTHERAPY
- Canagliflozin, a Novel SGLT2 Inhibitor for Treatment of Type 2 Diabetes
- (2014) Stefanie C. Nigro et al. ANNALS OF PHARMACOTHERAPY
- Renal failure in chronic liver disease and the hepatorenal syndrome
- (2014) Brijesh Srivastava et al. BRITISH JOURNAL OF HOSPITAL MEDICINE
- Pharmacokinetic and Pharmacodynamic Profile of Empagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor
- (2014) André J. Scheen CLINICAL PHARMACOKINETICS
- Quels bénéfices antitumoraux attendre de la metformine ?
- (2013) Emmanuel Beck et al. ANNALES D ENDOCRINOLOGIE
- The role of co-morbidity in the selection of antidiabetic pharmacotherapy in type-2 diabetes
- (2013) Diethelm Tschöpe et al. Cardiovascular Diabetology
- The Effect of Moderate Hepatic Impairment on the Pharmacokinetics of Ipragliflozin, a Novel Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor
- (2013) Wenhui Zhang et al. CLINICAL DRUG INVESTIGATION
- Clinical Pharmacokinetics and Pharmacodynamics of Dapagliflozin, a Selective Inhibitor of Sodium-Glucose Co-transporter Type 2
- (2013) Sreeneeranj Kasichayanula et al. CLINICAL PHARMACOKINETICS
- Metformin revisited: A critical review of the benefit–risk balance in at-risk patients with type 2 diabetes
- (2013) A.J. Scheen et al. DIABETES & METABOLISM
- Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
- (2013) Mei Zhang et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease
- (2013) André J Scheen Expert Opinion on Drug Metabolism & Toxicology
- Canagliflozin, an inhibitor of sodium–glucose cotransporter 2, for the treatment of type 2 diabetes mellitus
- (2013) Elizabeth M Lamos et al. Expert Opinion on Drug Metabolism & Toxicology
- Mitiglinide for type 2 diabetes treatment
- (2013) Haley M Phillippe et al. EXPERT OPINION ON PHARMACOTHERAPY
- Pharmacological profile, efficacy and safety of lixisenatide in type 2 diabetes mellitus
- (2013) Thomas Forst et al. EXPERT OPINION ON PHARMACOTHERAPY
- Efficacy and safety in sitagliptin therapy for diabetes complicated by non-alcoholic fatty liver disease
- (2013) Yasuji Arase et al. HEPATOLOGY RESEARCH
- Efficacy and safety of linagliptin in subjects with type 2 diabetes mellitus and poor glycemic control: Pooled analysis of data from three placebo-controlled phase III trials
- (2013) Stefano Del Prato et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Dipeptidyl peptidase-4: A key player in chronic liver disease
- (2013) Minoru Itou WORLD JOURNAL OF GASTROENTEROLOGY
- Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial
- (2013) Matthew J Armstrong et al. BMJ Open
- Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies
- (2013) Samuel S. Engel et al. Diabetes Therapy
- Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program
- (2012) M. J. Armstrong et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Pharmacokinetics of linagliptin in subjects with hepatic impairment
- (2012) Ulrike Graefe-Mody et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Clinical Pharmacokinetics and Pharmacodynamics of Vildagliptin
- (2012) Yan-Ling He CLINICAL PHARMACOKINETICS
- Comparative Clinical Pharmacokinetics of Dipeptidyl Peptidase-4 Inhibitors
- (2012) Larry K. Golightly et al. CLINICAL PHARMACOKINETICS
- Mechanisms Involved in the Protective Effects of Metformin Against Nonalcoholic Fatty Liver Disease
- (2012) V. J. Barbero-Becerra et al. CURRENT MEDICINAL CHEMISTRY
- Dorothy Hodgkin Lecture 2012* Non-alcoholic fatty liver disease, insulin resistance and ectopic fat: a new problem in diabetes management
- (2012) C. D. Byrne DIABETIC MEDICINE
- Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2012) S. E. Inzucchi et al. DIABETOLOGIA
- Dapagliflozin
- (2012) Greg L. Plosker DRUGS
- Repaglinide
- (2012) Lesley J. Scott DRUGS
- GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations
- (2012) Maria J Jespersen et al. Expert Opinion on Drug Metabolism & Toxicology
- Drug-induced hypoglycaemia in type 2 diabetes
- (2012) Berit Inkster et al. Expert Opinion On Drug Safety
- Saxagliptin overview: special focus on safety and adverse effects
- (2012) Shamsa Ali et al. Expert Opinion On Drug Safety
- Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin
- (2012) Stephen A. Harrison et al. HEPATOLOGY
- Liver and diabetes. A vicious circle
- (2012) Paola Loria et al. HEPATOLOGY RESEARCH
- Managing Diabetes in Patients with Chronic Liver Disease
- (2012) Roaid Khan et al. POSTGRADUATE MEDICINE
- The Effectiveness of Liraglutide in Nonalcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Compared to Sitagliptin and Pioglitazone
- (2012) Takamasa Ohki et al. TheScientificWorldJOURNAL
- Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Saxagliptin
- (2011) David W. Boulton et al. CLINICAL PHARMACOKINETICS
- Clinical Pharmacokinetics of Metformin
- (2011) Garry G. Graham et al. CLINICAL PHARMACOKINETICS
- Influence of Hepatic Impairment on the Pharmacokinetics and Safety Profile of Dapagliflozin: An Open-Label, Parallel-Group, Single-Dose Study
- (2011) Sreeneeranj Kasichayanula et al. CLINICAL THERAPEUTICS
- The Role of Metformin in the Management of NAFLD
- (2011) Angela Mazza et al. Experimental Diabetes Research
- Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation)
- (2011) André J Scheen Expert Opinion on Drug Metabolism & Toxicology
- A review of gliptins in 2011
- (2011) André J Scheen EXPERT OPINION ON PHARMACOTHERAPY
- Sitagliptin as a Novel Treatment Agent for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus
- (2011) Tomoyuki Iwasaki et al. HEPATO-GASTROENTEROLOGY
- Efficacy and safety in sitagliptin therapy for diabetes complicated by chronic liver disease caused by hepatitis C virus
- (2011) Yasuji Arase et al. HEPATOLOGY RESEARCH
- A Case of Drug-induced Hepatic Injury Associated with Sitagliptin
- (2011) Megumi Toyoda-Akui et al. INTERNAL MEDICINE
- Impact of Metformin on the Prognosis of Cirrhosis Induced by Viral Hepatitis C in Diabetic Patients
- (2011) Gisèle Nkontchou et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Impact of liver diseases on the development of type 2 diabetes mellitus
- (2011) Po-Shiuan Hsieh WORLD JOURNAL OF GASTROENTEROLOGY
- The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis
- (2011) Lisa B. Van Wagner et al. Therapeutic Advances in Gastroenterology
- Pioglitazone in the treatment of NASH: the role of adiponectin
- (2010) A. Gastaldelli et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Elevated Hepatic Enzymes Potentially Associated with Sitagliptin
- (2010) Benjamin N Gross et al. ANNALS OF PHARMACOTHERAPY
- Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide
- (2010) Anne Flint et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Pharmacokinetics of dipeptidylpeptidase-4 inhibitors
- (2010) A. J. Scheen DIABETES OBESITY & METABOLISM
- An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials
- (2010) M. Ligueros-Saylan et al. DIABETES OBESITY & METABOLISM
- Role of Continuous Subcutaneous Insulin Infusion (Insulin Pump) in Reducing Blood Glucose in Four Patients with Type 2 Diabetes and Cirrhosis: A Case Series
- (2010) Johny J. Kannampilly Diabetes Technology & Therapeutics
- Metabolism and Excretion of the Once-Daily Human Glucagon-Like Peptide-1 Analog Liraglutide in Healthy Male Subjects and Its In Vitro Degradation by Dipeptidyl Peptidase IV and Neutral Endopeptidase
- (2010) M. Malm-Erjefalt et al. DRUG METABOLISM AND DISPOSITION
- Lactic Acidosis Induced by Metformin
- (2010) Jean-Daniel Lalau DRUG SAFETY
- Clarifying metformin's role and risks in liver dysfunction
- (2010) Carolyn C. Brackett JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION
- Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease
- (2010) Valter Donadon et al. LIVER INTERNATIONAL
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
- (2010) Arun J. Sanyal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Selection and Dosing of Medications for Management of Diabetes in Patients with Advanced Kidney Disease
- (2010) James B. Reilly et al. SEMINARS IN DIALYSIS
- Thiazolidinediones and the liver in humans
- (2009) Hannele Yki-Järvinen CURRENT OPINION IN LIPIDOLOGY
- Liver Safety in Patients with Type 2 Diabetes Treated with Pioglitazone
- (2009) Keith G. Tolman et al. DRUG SAFETY
- Pioglitazone improves virological response to peginterferon α-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance
- (2009) Mahmoud Khattab et al. LIVER INTERNATIONAL
- Liver cirrhosis and diabetes: Risk factors, pathophysiology, clinical implications and management
- (2009) Diego Garcia-Compean et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction
- (2008) Roger K. Verbeeck EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Different Effects ofSLCO1B1Polymorphism on the Pharmacokinetics and Pharmacodynamics of Repaglinide and Nateglinide
- (2008) Annikka Kalliokoski et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide
- (2008) Annikka Kalliokoski et al. Pharmacogenetics and Genomics
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More